Nanosized aspirin-arg-gly-asp-val: Delivery of aspirin to thrombus by the target carrier arg-gly-asp-val tetrapeptide

ACS Nano

Volumn 7, Issue 9, 2013, Pages 7664-7673

  Jin, Shaoming ^a   Wang, Yaonan ^a   Zhu, Haimei ^a   Wang, Yuji ^a   Zhao, Shurui ^a   Zhao, Ming ^a,b   Liu, Jiawang ^a   Wu, Jianhui ^a   Gao, Wen ^a   Peng, Shiqi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

aspirin; cyclooxygenase; GPIIb IIIa; nanomedicine; RGDV; thrombus

Indexed keywords

ASPIRIN; CYCLOOXYGENASES; GPIIB/IIIA; RGDV; THROMBUS;

ATOMIC FORCE MICROSCOPY; BLOOD; DRUG DELIVERY; ENZYME INHIBITION; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; OLIGOMERS; RATS; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

BLOOD VESSELS;

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARGINYL GLYCYL ASPARTYL VALINE; ARGINYL-GLYCYL-ASPARTYL-VALINE; CYCLOOXYGENASE 1; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; NANOCAPSULE; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOPEPTIDE;

ANIMAL; ARTICLE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; MALE; METABOLISM; RAT; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; MALE; NANOCAPSULES; OLIGOPEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RATS, WISTAR; THROMBOSIS; TREATMENT OUTCOME;

EID: 84884944084     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn402171v     Document Type: Article

References (51)

1. Castro, P.; Nasser, H.; Abrahão, A.; Dos Reis, L. C.; Riça, I.; Valença, S. S.; Rezende, D. C.; Quintas, L. E.; Cavalcante, M. C.; Porto, L. C. et al. Aspirin and Indomethacin Reduce Lung Inflammation of Mice Exposed to Cigarette Smoke Biochem. Pharmacol. 2009, 77, 1029-1039
2. Liu, J. Y.; Yang, J.; Inceoglu, B.; Qiu, H.; Ulu, A.; Hwang, S. H.; Chiamvimonvat, N.; Hammock, B. D. Inhibition of Soluble Epoxide Hydrolase Enhances the Anti-Inflammatory Effects of Aspirin and 5-Lipoxygenase Activation Protein Inhibitor in a Murine Model Biochem. Pharmacol. 2010, 79, 880-887
3. Cholette, J. M.; Mamikonian, L.; Alfieris, G. M.; Blumberg, N.; Lerner, N. B.; Jill, M.; Cholette, L. M.; George, M.; Alfieris, N. B.; Norma, B. L. Aspirin Resistance Following Pediatric Cardiac Surgery Thromb. Res. 2010, 126, 200-206
4. Wong, S.; Appleberg, M.; Ward, C. M.; Lewis, D. R. Aspirin Resistance in Cardiovascular Disease: A Review Eur. J. Vasc. Endovasc. Surg. 2004, 27, 456-465
5. Carmignani, L.; Picozzi, S.; Bozzini, G.; Negri, E.; Ricci, C.; Gaeta, M.; Pavesi, M. Transrectal Ultrasound-Guided Prostate Biopsies in Patients Taking Aspirin for Cardiovascular Disease: A Meta-Analysis Transfus. Apheresis Sci. 2011, 45, 275-280
6. Berger, J. S.; Lala, A.; Krantz, M. J.; Baker, G. S.; Hiatt, W. R. Aspirin for the Prevention of Cardiovascular Events in Patients without Clinical Cardiovascular Disease: A Meta-Analysis of Randomized Trials Am. Heart. J. 2011, 162, 115-124.e2
7. Lamotte, M.; Piñol, C.; Brotons, C.; Annemans, L.; Guardiola, E.; Evers, T.; Kubin, M. Health Economic Evaluation of Low-Dose Acetylsalicylic Acid in the Primary Prevention of Cardiovascular Disease Rev. Esp. Cardiol. 2006, 59, 807-815
8. Chaturvedi, S. Acetylsalicylic Acid + Extended-Release Dipyridamole Combination Therapy for Secondary Stroke Prevention Clin. Ther. 2008, 30, 1196-1205
9. Meyer, D. M.; Albright, K. C.; Allison, T. A.; Grotta, J. C. LOAD: A Pilot Study of the Safety of Loading of Aspirin and Clopidogrel in Acute Ischemic Stroke and Transient Ischemic Attack J. Stroke Cerebrovasc. Dis. 2008, 17, 26-29
10. Rey, E.; Rivard, G. E. Is Testing for Aspirin Response Worthwhile in High-Risk Pregnancy? Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 157, 38-42
11. Perneby, C.; Vahter, M.; Akesson, A.; Bremme, K.; Hjemdahl, P. Thromboxane Metabolite Excretion during Pregnancy-Influence of Preeclampsia and Aspirin Treatment Thromb. Res. 2011, 127, 605-606
12. Schrör, K. Pharmacology and Cellular/Molecular Mechanisms of Action of Aspirin and Non-Aspirin NSAIDs in Colorectal Cancer Best Pract. Res. Clin. Gastroenterol. 2011, 25, 473-484
13. Lim, W. Y.; Chuah, K. L.; Eng, P.; Leong, S. S.; Lim, E.; Lim, T. K.; Ng, A.; Poh, W. T.; Tee, A.; Teh, M. et al. Aspirin and Non-Aspirin Non-Steroidal Anti-Inflammatory Drug Use and Risk of Lung Cancer Lung Cancer 2012, 77, 246-251
14. Garcia-Albeniz, X.; Chan, A. T. Aspirin for the Prevention of Colorectal Cancer Best Pract. Res. Clin. Gastroenterol. 2011, 25, 461-472
15. Yassine, H. N.; Davis-Gorman, G.; Stump, C. S.; Thomson, S. S.; Peterson, J.; McDonagh, P. F. Clinical Determinants of Aspirin Resistance in Diabetes Diabetes Res. Clin. Pract. 2010, 90, e19-e21
16. Zhang, C.; Sun, A.; Zhang, P.; Wu, C.; Zhang, S.; Fu, M.; Wang, K.; Zou, Y.; Ge, J. Aspirin for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Meta-Analysis Diabetes Res. Clin. Pract. 2010, 87, 211-218
17. Lin, L.; Cao, J.; Fan, L.; Hu, G.; Hu, Y.; Zhu, B.; Li, X.; Wang, H.; Bai, J.; Shi, H. Prevalence and Risk Factors for Aspirin Resistance in Elderly Patients with Type 2 Diabetes Int. J. Gerontol. 2011, 5, 112-116
18. Duzenli, M. A.; Ozdemir, K.; Aygul, N.; Soylu, A.; Tokac, M. Comparison of Increased Aspirin Dose versus Combined Aspirin plus Clopidogrel Therapy in Patients with Diabetes Mellitus and Coronary Heart Disease and Impaired Antiplatelet Response to Low-Dose Aspirin Am. J. Cardiol. 2008, 102, 396-400
19. Pomponi, M. F.; Gambassi, G.; Pomponi, M.; Di Gioia, A.; Masullo, C. Why Docosahexaenoic Acid and Aspirin Supplementation Could Be Useful in Women as a Primary Prevention Therapy against Alzheimer's Disease? Ageing Res. Rev. 2011, 10, 124-131
20. Caraci, F.; Copani, A.; Nicoletti, F.; Drago, F. Depression and Alzheimer's Disease: Neurobiological Links and Common Pharmacological Targets Eur. J. Pharmacol. 2010, 626, 64-71
21. Le Guyader, A.; Pacheco, G.; Seaver, N.; Davis-Gorman, G.; Copeland, J.; McDonagh, P. F. Inhibition of Platelet GPIIb-IIIa and P-Selectin Expression by Aspirin Is Impaired by Stress Hyperglycemia J. Diabetes Complications 2009, 23, 65-70
22. Shaker, M.; Lobb, A.; Jenkins, P.; O'Rourke, D.; Takemoto, S. K.; Sheth, S.; Burroughs, T.; Dykewicz, M. S. An Economic Analysis of Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease J. Allergy Clin. Immunol. 2008, 121, 81-87
23. Stevenson, D. D.; Simon, R. A. Selection of Patients for Aspirin Desensitization Treatment J. Allergy Clin. Immunol. 2006, 118, 801-804
24. Wong, S.; Appleberg, M.; Ward, C. M.; Lewis, D. R. Aspirin Resistance in Cardiovascular Disease: A Review Eur. J. Vasc. Endovasc. Surg. 2004, 27, 456-465
25. Poulsen, T. S.; Kristensen, S. R.; Korsholm, L.; Haghfelt, T.; Jørgensen, B.; Licht, P. B.; Mickley, H. Variation and Importance of Aspirin Resistance in Patients with Known Cardiovascular Disease Thromb. Res. 2007, 120, 477-484
26. Seok, J. I.; Joo, I. S.; Yoon, J. H.; Choi, Y. J.; Lee, P. H.; Huk, K.; Bang, O. Y. Can Aspirin Resistance be Clinically Predicted in Stroke Patients? Clin. Neurol. Neurosurg. 2008, 110, 110-116
27. Hobikoglu, G. F.; Norgaz, T.; Aksu, H.; Ozer, O.; Erturk, M.; Destegul, E.; Akyuz, U.; Unal Dai, S.; Narin, A. The Effect of Acetylsalicylic Acid Resistance on Prognosis of Patients Who have Developed Acute Coronary Syndrome during Acetylsalicylic Acid Therapy Can. J. Cardiol. 2007, 23, 201-206
28. Pui-Yin, L.; Wai-Hong, C.; William, N.; Xi, C.; Jeanette, Y. K.; Hung-Fat, T.; Chu-Pak, L. Low-Dose Aspirin Increases Aspirin Resistance in Patients with Coronary Artery Disease Am. J. Med. 2005, 118, 723-727
29. Cholette, J. M.; Mamikonian, L.; Alfieris, G. M.; Blumberg, N.; Lerner, N. B. Aspirin Resistance Following Pediatric Cardiac Surgery Thromb. Res. 2010, 126, 200-206
30. Watala, W.; Golanski, J.; Pluta, J.; Boncler, M.; Rozalski, M.; Luzak, B.; Kropiwnicka, A.; Drzewoski, J. Reduced Sensitivity of Platelets from Type 2 Diabetic Patients to Acetylsalicylic Acid (Aspirin)-Its Relation to Metabolic Control Thromb. Res. 2004, 113, 101-113
31. Boncler, M.; Gresner, P.; Nocun, M.; Rywaniak, J.; Dolnik, M.; Rysz, J.; Wilk, R.; Czyz, M.; Markuszewski, L.; Banach, M. et al. Elevated Cholesterol Reduces Acetylsalicylic Acid-Mediated Platelet Acetylation Biochim. Biophys. Acta 2007, 1770, 1651-1659
32. Chapman, M. J. From Pathophysiology to Targeted Therapy for Atherothrombosis: A Role for the Combination of Statin and Aspirin in Secondary Prevention Pharmacol. Ther. 2007, 113, 184-196
33. Juzwa, M.; Rusin, A.; Zawidlak-Wegrzyńska, B.; Krawczyk, Z.; Obara, I.; Jedliński, Z. Oligo(3-Hydroxybutanoate) Conjugates with Acetylsalicylic Acid and their Antitumour Activity Eur. J. Med. Chem. 2008, 43, 1785-1790
34. Jenneck, C.; Juergens, U.; Buecheler, M.; Novak, N. Pathogenesis, Diagnosis, and Treatment of Aspirin Intolerance Ann. Allergy, Asthma, Immunol. 2007, 99, 13-21
35. White, A.; Ludington, E.; Mehra, P.; Stevenson, D. D.; Simon, R. A. Effect of Leukotriene Modifier Drugs on the Safety of Oral Aspirin Challenges Ann. Allergy, Asthma, Immunol. 2006, 97, 688-693
36. Zhang, Z.; Lai, Y.; Yu, L.; Ding, J. Effects of Immobilizing Sites of RGD Peptides in Amphiphilic Block Copolymers on Efficacy of Cell Adhesion Biomaterials 2010, 31, 7873-7882
37. Hennessy, K. M.; Clem, W. C.; Phipps, M. C.; Sawyer, A. A.; Shaikh, F. M.; Bellis, S. L. The Effect of RGD Peptides on Osseointegration of Hydroxyapatite Biomaterials Biomaterials 2008, 29, 3075-3083
38. Rafiuddin Ahmed, M.; Jayakumar, R. Peripheral Nerve Regeneration in RGD Peptide Incorporated Collagen Tubes Brain Res. 2003, 993, 208-216
39. Kalinina, S.; Gliemann, H.; López-García, M.; Petershans, A.; Auernheimer, J.; Schimmel, T.; Bruns, M.; Schambony, A.; Kessler, H.; Wedlich, D.; Isothiocyanate-Functionalized, R. G. D. Peptides for Tailoring Cell-Adhesive Surface Patterns Biomaterials 2008, 29, 3004-3013
40. Hwang, D. S.; Sim, S. B.; Cha, H. J. Cell Adhesion Biomaterial Based on Mussel Adhesive Protein Fused with RGD Peptide Biomaterials 2007, 28, 4039-4046
41. Hagisawa, K.; Nishioka, T.; Suzuki, R.; Takizawa, T.; Maruyama, K.; Takase, B.; Ishihara, M.; Kurita, A.; Yoshimoto, N.; Ohsuzu, F. et al. Enhancement of Ultrasonic Thrombus Imaging Using Novel Liposomal Bubbles Targeting Activated Platelet Glycoprotein IIb/IIIa Complex-In Vitro and In Vivo Study Int. J. Cardiol. 2011, 152, 202-206
42. Sánchez-Cortés, J.; Mrksich, M. The Platelet Integrin αIIbβ3 Binds to the RGD and AGD Motifs in Fibrinogen Chem. Biol. 2009, 16, 990-1000
43. Barre, D. E. Arginyl-Glycyl-Aspartyl (RGD) Epitope of Human Apolipoprotein (a) Inhibits Platelet Aggregation by Antagonizing the IIb Subunit of the Fibrinogen (GPIIb/IIIa) Receptor Thromb. Res. 2007, 119, 601-607
44. Kupczyk, M.; Kurmanowska, Z.; Kupryś-Lipińska, I.; Bocheńska-Marciniak, M.; Kuna, P. Mediators of Inflammation in Nasal Lavage from Aspirin Intolerant Patients after Aspirin Challenge Resp. Med. 2010, 104, 1404-1409
45. Vaidya, B.; Nayak, M. K.; Dash, D.; Agrawal, G. P.; Vyas, S. P. Development and Characterization of Site Specific Target Sensitive Liposomes for the Delivery of Thrombolytic Agents Int. J. Pharmaceut. 2011, 403, 254-261
46. Lukasik, M.; Dworacki, G.; Michalak, S.; Kufel-Grabowska, J.; Golanski, J.; Watala, C.; Kozubski, W. Aspirin Treatment Influences Platelet-Related Inflammatory Biomarkers in Healthy Individuals but Not in Acute Stroke Patients Thromb. Res. 2011, 128, e73-e80
47. Fujita, Y.; Mie, M.; Kobatake, E. Construction of Nanoscale Protein Particle Using Temperature-Sensitive Elastin-Like Peptide and Polyaspartic Acid Chain Biomaterials 2009, 30, 3450-3457
48. Prasad, R. Y.; Wallace, K.; Daniel, K. M.; Tennant, A. H.; Zucker, R. M.; Strickland, J.; Dreher, K.; Kligerman, A. D.; Blackman, C. F.; DeMarini, D. M. Effect of Treatment Media on the Agglomeration of Titanium Dioxide Nanoparticles: Impact on Genotoxicity, Cellular Interaction, and Cell Cycle ACS Nano 2013, 7, 1929-1942
49. Herd, H.; Daum, N.; Jones, A. T.; Huwer, H.; Ghandehari, H.; Leh, C. M. Nanoparticle Geometry and Surface Orientation Influence Mode of Cellular Uptake ACS Nano 2013, 7, 1961-1973
50. Barth, B. M.; Shanmugavelandy, S. S.; Kaiser, J. M.; McGovern, C.; AltnogÌlu, E. I.; Haakenson, J. K.; Hengst, J. A.; Gilius, E. L.; Knupp, S. A.; Fox, T. E. et al. Photoimmunonanotherapy Reveals an Anticancer Role for Sphingosine Kinase 2 and Dihydrosphingosine-1-Phosphate ACS Nano 2013, 7, 2132-2144
51. Stefanick, J. F.; Ashley, J. D.; Kiziltepe, T.; Bilgicer, B. A Systematic Analysis of Peptide Linker Length and Liposomal Polyethylene Glycol Coating on Cellular Uptake of Peptide-Targeted Liposomes ACS Nano 2013, 7, 2935-2947